Clinical Trial Update: An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating multiple administration regimens of nivolumab plus ipilimumab in renal cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-12-19